ERBB2 and neoplasm: We show that the desARE3'UTRERBB2-30 constructs packaged into IO nanocages achieved 50% therapeutic inhibition of the tumor, 80% malignant cell reduction, 50% complete tumor lysis, and 60% complete reduction of ERBB2 IHC (Figures 1A–L).